Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
04/2010
04/15/2010WO2010041255A2 Liposomal systems comprising sphingomyelin
04/15/2010WO2010041253A1 Compositions comprising cb receptor agonists, uses thereof and methods for their preparation
04/15/2010WO2010041219A1 2-benzothiophenyl-and 2-naphthyl-0xaz0lidin0nes and their azaisostere analogues as antibacterial agents
04/15/2010WO2010041218A2 Oxazolidinyl antibiotics
04/15/2010WO2010041194A1 Tricyclic oxazolidinone antibiotic compounds
04/15/2010WO2010041162A1 Tetrahydrofuranyl sulfonamides for use as ampa modulators in the treatment of cns disorders
04/15/2010WO2010041144A2 Beta-hydroxy-gamma-aminophosphonates and methods for the preparation and use thereof
04/15/2010WO2010041143A2 Oral vaccines for producing mucosal immunity
04/15/2010WO2010041140A2 Treatment of proliferative disorders with a death receptor agonist
04/15/2010WO2010041138A2 Complex between human insulin and an amphiphilic polymer, and use of said complex for preparing a quick human insulin formulation
04/15/2010WO2010041119A1 Polysaccharides containing carboxyl functional groups substituted by a hydrophobic alcohol derivative
04/15/2010WO2010041112A1 Novel combinations of antibacterial nitrogenous heterocyclic compounds with other antibacterial compounds, and use thereof as drugs
04/15/2010WO2010041108A1 Nitrogenous heterocyclic compounds, preparation thereof, and use thereof as antibacterial agents
04/15/2010WO2010041100A1 Using of organic solvents in wet granulation of moxifloxacin
04/15/2010WO2010041097A1 New vaccine adjuvants
04/15/2010WO2010041054A1 Pyridine and pyrimidine based compounds as wnt signaling pathway inhibitors for the treatment of cancer
04/15/2010WO2010041017A2 Chewable gelled emulsions
04/15/2010WO2010040992A1 Quinoline derivatives having dp and / or crth2 receptor activity
04/15/2010WO2010040854A1 18f-labelled folates as pet radiotracers
04/15/2010WO2010040843A2 Dibenzocycloheptanone derivatives and pharmaceutical agents containing said compounds
04/15/2010WO2010040839A1 Antimicrobial compositions and uses
04/15/2010WO2010040826A1 6-phenyl-pyrimidin-4-yl-(phenylamine or phenoxy) derivatives useful as modulators of nicotinic acetylcholine receptors
04/15/2010WO2010040808A1 Novel quinolinylamide derivatives useful as modulators of dopamine and serotonin receptors
04/15/2010WO2010040803A2 Kv1.3 channel blocking substances for the treatment of diseases associated with intimal hyperplasia
04/15/2010WO2010040765A1 Antiprolactinic veterinary composition for ruminants
04/15/2010WO2010040762A1 New amide compounds as boosters of antivirals
04/15/2010WO2010040750A1 3, 3', 4, 4' -tetrahydroxy-2, 2' -bipyridine-n, n' -dioxides for the treatment of renal cell carcinoma
04/15/2010WO2010040663A1 Pyrrolidine n-benzyl derivatives
04/15/2010WO2010040661A1 Modulators for amyloid beta
04/15/2010WO2010040652A1 Liquid pharmaceutical formulation containing paracetamol
04/15/2010WO2010040632A1 Modified release emulsions for application to skin or vaginal mucosa
04/15/2010WO2010040603A1 Dithiolane compounds; compositions containing them; uses for photoprotecting the skin
04/15/2010WO2010040562A1 A polymer-free hydrogel
04/15/2010WO2010040527A1 Novel compounds which modulate kinase activity
04/15/2010WO2010040461A1 Method for the preparation of functionalized trihalomethoxy substituted pyridines
04/15/2010WO2010040317A1 Mixture of oligosaccharides of heparin derivatives and its preparation and medicament
04/15/2010WO2010040315A1 The 1-butyl-2-hydroxyaralkyl piperazine derivatives and the uses as anti-depression medicine thereof
04/15/2010WO2010040312A1 Composite material and its prepration, using in tumor therapy and aititumor medicine
04/15/2010WO2010040286A1 Triacetyl-3-hydroxyphenyladenosine and its use for regulating blood fat
04/15/2010WO2010040275A1 The 2-(4-substituted phenylamino) polysubstituted pyridine compounds as the inhibitors of non-nucleoside hiv reverse transcriptase, praparation methods and uses thereof
04/15/2010WO2010040274A1 Novel dopamine d3 receptor ligands, the preparation and use thereof
04/15/2010WO2010040272A1 Amide compounds, their pharmaceutical compositions, their preparation and their use
04/15/2010WO2010040254A1 The use of flavones from radix scutellariae in manufacture of medicaments for treating enterovirus infection
04/15/2010WO2010040252A1 Epothilone glycoside compounds, compositions containing epothilone glycoside compounds as active components and uses thereof
04/15/2010WO2010040232A1 Use of scyllo-inositols for the treatment of macular degeneration-related disorders
04/15/2010WO2010040212A1 Processes for the preparation of erlotinib hydrochloride
04/15/2010WO2010040188A1 Biodegradable polymer - bioactive moiety conjugates
04/15/2010WO2010040184A1 Systems, methods, and devices for rehabilitation of auditory system disorders using pharmaceutical agents and auditory devices
04/15/2010WO2010023498A8 Methods of enhancing adjuvanticity of vaccine compositions
04/15/2010WO2010022382A3 Crosslinked polyfluoroacrylic acid and processes for the preparation thereof
04/15/2010WO2010022249A3 Macrocyclic compounds for inhibition of tumor necrosis factor alpha
04/15/2010WO2010021717A3 Hcv protease inhibitors
04/15/2010WO2010021680A3 Inhibitors of beta-secretase
04/15/2010WO2010019611A3 Bridged polycyclic compound based compositions for topical and oral applications
04/15/2010WO2010018837A3 Protein cross-linking inhibitor
04/15/2010WO2010018836A3 Polyglutamine aggregation inhibitor
04/15/2010WO2010018593A3 Gastric acid resistant benzimidazole multiple unit tablet composition
04/15/2010WO2010017035A3 Inhibitors of iap
04/15/2010WO2010014888A3 Use of a pneumococcal p4 peptide for enhancing opsonophagocytosis in response to a pathogen
04/15/2010WO2010014784A9 Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
04/15/2010WO2010012965A3 Combination of a tlr3 ligand and a chemotherapy agent which acts on the intrinsic “apoptosis” pathway in the treatment of cancer
04/15/2010WO2010012817A3 5ht7 receptor ligands and compositions comprising the same
04/15/2010WO2010011845A3 Preventing or treating viral infection using an inhibitor of the lsd1 protein, a mao inhibitor or an inhibitor of lsdl and a mao inhibitor
04/15/2010WO2010008203A3 Pharmaceutical formulation containing a calcium channel blocker
04/15/2010WO2010006169A3 2-methylene-19, 26-dinor-(20s, 22e, 25r)-vitamin d analogs
04/15/2010WO2010006135A3 2-methylene-(17z)-17(20)-dehydro-19,21-dinor-vitamin d analogs
04/15/2010WO2010006086A3 Kinase inhibitors and methods of use
04/15/2010WO2010005558A3 Pi3k isoform selective inhibitors
04/15/2010WO2010005310A3 Complement antagonists and uses thereof
04/15/2010WO2010003127A3 Antagonists of prostaglandin d2 receptors
04/15/2010WO2010002209A3 Novel compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist and pharmaceutical compositions containing the same
04/15/2010WO2010000903A3 Composition capable of modulating ikkalpha activity for the treatment of diseases associated with acantholysis
04/15/2010WO2009158487A3 Treatment of nephrolithiasis and urolithiasis using 1,2,3,4,6-penta-o-galloyl-beta-d-glucose (pgg)
04/15/2010WO2009152347A3 Crystalline forms of zotepine hydrochloride
04/15/2010WO2009148600A3 Deuterated lysine-based compounds
04/15/2010WO2009146218A3 Compounds including an anti-inflammatory pharmacore and methods of use
04/15/2010WO2009143018A3 Pyrrolo [2, 3-d] pyrimidines as fm and kit kinase modulators
04/15/2010WO2009139655A3 The use of an exopolysaccharide fraction produced by Lactobacillus rhamnosus
04/15/2010WO2009129460A4 Clonidine formulations in a biodegradable polymer carrier
04/15/2010WO2009125434A3 Oxime derivatives, process for their preparation, pharmaceutical composition containing the same and medicinal use thereof
04/15/2010WO2009120697A4 Method and compositions for treatment of cancer
04/15/2010WO2009112021A3 Pharmaceutical composition for the diagnosis or treatment of a plasmocytoma
04/15/2010WO2009110003A8 Novel flavonol compounds, a bioactive extract/fraction from ulmus wallichiana and its compounds for prevention for treatment of osteo-health related disorders
04/15/2010WO2009071753A8 4-phenyl-1,3-thiazole and 4-phenyl-1,3-oxazole derivatives as cannabinoid receptor ligands
04/15/2010WO2008075376A8 Polymorphic forms of bortezomib and process for their preparation
04/15/2010WO2005074981A8 Inhibitors of tgf-r signaling for treatment of cns disorders
04/15/2010US20100095398 Protection against environmental toxicity through manipulation of the processing of messenger RNA precursors
04/15/2010US20100095391 Regulation of lipid droplet formation by modulation of fit1 and fit2 and uses thereof
04/15/2010US20100094408 Drug-Delivery Endovascular Stent and Method for Treating Restenosis
04/15/2010US20100094041 Anti-inflammatory and psoriasis treatment and protein kinase inhibition by hydroxy stilbenes and novel stilbene derivatives and analogues
04/15/2010US20100094026 Method of screening compound useful in treating allergic disease
04/15/2010US20100094016 Thiazoline acid derivatives
04/15/2010US20100094002 Thiazole Compound and Use Thereof
04/15/2010US20100093873 Methods of improving therapy of perfluorocarbons (PFC)
04/15/2010US20100093872 Stable aqueous formulations of water insoluble or poorly soluble drugs
04/15/2010US20100093871 Agent for prevention or treatment of iron overload disorders
04/15/2010US20100093870 Herbal medicaments for the treatment of neurocerebrovascular disorders
04/15/2010US20100093869 Sensation masking composition
04/15/2010US20100093868 Water-soluble metal-processing agent, coolant, method for preparation of the coolant, method for prevention of microbial deterioration of water-soluble metal-processing agent, and metal processing
04/15/2010US20100093867 Method Of Treating Genetic Disease Caused By Nonsense Mutation